ACC 2026: Baxdrostat lowers BP in uncontrolled hypertension
At the 2026 ACC, researchers presented a meta-analysis of three trials (1,264 patients) assessing baxdrostat’s blood pressure and safety effects in uncontrolled hypertension.
Therapy Area
ACC 2026: Lorundrostat lowers BP but raises hyperkalemia risk
Merck’s strategic shift: acquires Terns for $6.7bn, targeting dominance in CML
Improving early detection and treatment of liver cancer
Transient but transformative: Sanofi’s mRNA CAR-T enters in vivo race
UK health authorities join forces to champion foreign infectious disease trials
Multiple Myeloma Awareness Month: the current and future landscape
Targeted therapies to join chemo as oncology treatment backbone
